Nektar optimistic despite pain drug's Phase II failure
This article was originally published in Scrip
Executive Summary
The Nektar Therapeutics mu-opioid agonist NKTR-181 for the treatment of pain with fewer opioid-associated side effects, including addiction, did not meet the primary endpoint in a Phase II clinical trial for pain associated with osteoarthritis of the knee.